Compare VIK & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VIK | WAT |
|---|---|---|
| Founded | 1997 | 1958 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.3B | 22.5B |
| IPO Year | 2024 | 1995 |
| Metric | VIK | WAT |
|---|---|---|
| Price | $74.07 | $400.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 16 |
| Target Price | $69.38 | ★ $390.67 |
| AVG Volume (30 Days) | ★ 1.8M | 518.5K |
| Earning Date | 02-24-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.82 |
| EPS | 2.11 | ★ 10.88 |
| Revenue | ★ $6,126,790,000.00 | $3,105,638,000.00 |
| Revenue This Year | $21.13 | $7.96 |
| Revenue Next Year | $14.58 | $6.32 |
| P/E Ratio | ★ $35.14 | $36.83 |
| Revenue Growth | ★ 20.04 | 6.90 |
| 52 Week Low | $31.79 | $275.05 |
| 52 Week High | $74.61 | $423.56 |
| Indicator | VIK | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 66.69 | 64.32 |
| Support Level | $70.55 | $373.54 |
| Resistance Level | $74.61 | $408.67 |
| Average True Range (ATR) | 1.45 | 7.32 |
| MACD | -0.17 | 1.29 |
| Stochastic Oscillator | 89.25 | 78.79 |
Viking Holdings Ltd is a travel company, with a fleet of 92 small ships, which view as floating hotels. It offers travel experiences on all seven continents in all three categories of the cruise industry river, ocean, and expedition cruising. The Group defines its products based on the type of cruise offering and language of the cruise service. The River segment provides river cruises outside the United States to English-speaking passengers. The Ocean segment offers ocean cruises to English-speaking passengers. Other include operating segments that are not individually reportable, consisting of expedition cruises for English-speaking passengers (Expedition), Mississippi River cruises for English-speaking passengers, and Viking China, which includes cruises for Mandarin.
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.